论文部分内容阅读
目的:观察参仙升脉口服液联合茶碱缓释胶囊治疗老年窦性心动过缓的临床疗效和不良反应。方法:将老年窦性心动过缓129例随机分为观察组69例和对照组60例。对照组采用口服茶碱缓释胶囊治疗,观察组在口服茶碱缓释胶囊的同时加服参仙升脉口服液。两组均治疗8周,比较2组用药后临床症状、常规心电图、动态心电图改善及不良反应等。结果:观察组临床症状缓解总有效率86.9%,显效率57.9%,对照组总有效率68.3%,显效率33.3%,观察组显著优于对照组(P<0.05)。治疗后,观察组心率和24 h总心搏数为(64±6)/min和(8.258±0.359)万次,对照组为(52±8)/min和(7.718±0.628)万次,两组比较,差异显著(P<0.05)。两组均未发现严重不良反应。结论:参仙升脉口服液联合茶碱缓释胶囊治疗老年窦性心动过缓疗效优于单纯口服茶碱缓释胶囊。
Objective: To observe the clinical efficacy and side effects of Shenxian Shengmai Oral Liquid combined with theophylline sustained-release capsules in the treatment of senile sinus bradycardia. Methods: A total of 129 elderly patients with sinus bradycardia were randomly divided into observation group (69 cases) and control group (60 cases). The control group was treated with oral theophylline sustained-release capsules, and the observation group was given orally the ascending Shengmai Oral Liquid while taking theophylline sustained-release capsules. The two groups were treated for 8 weeks. The clinical symptoms, routine electrocardiogram, improvement of dynamic electrocardiogram and adverse reactions in two groups were compared. Results: The total effective rate of clinical symptoms relieved in observation group was 86.9%, markedly effective rate was 57.9%. The total effective rate in control group was 68.3%, the effective rate was 33.3%. The observation group was significantly better than the control group (P <0.05). After treatment, heart rate and total heart rate at 24 h were (64 ± 6) / min and (8.258 ± 0.359) respectively in the observation group and (52 ± 8) / min and (7.718 ± 0.628) Group, the difference was significant (P <0.05). No serious adverse reactions were found in either group. Conclusion: The effect of Shenxian Shengmai Oral Liquid combined with theophylline sustained-release capsules in the treatment of senile sinus bradycardia is superior to that of the simple oral theophylline sustained-release capsules.